In conclusion, PU.1 inhibition can attenuate Ang‐II‐induced atrial fibrosis and consequently decrease vulnerability to AF by suppressing activation of the TGF‐β1/Smads pathway. The gene discussed is AGT; the disease is atrial fibrillation.